Zheng-Gang Ren

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3735932/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming. Molecular Therapy, 2022, 30, 2554-2567.	8.2	24
2	Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. Academic Radiology, 2021, 28, S157-S166.	2,5	16
3	Prognostic significance of preoperative systemic immune-inflammation index in combined hepatocellular-cholangiocarcinoma. Cancer Biomarkers, 2021, 31, 1-15.	1.7	5
4	Development of a Prognostic Scoring System for Hepatocellular Carcinoma Patients With Main Portal Vein Tumor Thrombus Undergoing Conventional Transarterial Chemoembolization: An Analysis of 173 Patients. Frontiers in Oncology, 2021, 11, 671171.	2.8	4
5	Camrelizumab plus oxaliplatinâ€based chemotherapy as firstâ€line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. International Journal of Cancer, 2021, 149, 1944-1954.	5.1	32
6	Albumin-to-alkaline phosphatase ratio as a predictor of tumor recurrence and prognosis in patients with early-stage hepatocellular carcinoma undergoing radiofrequency ablation as initial therapy. International Journal of Hyperthermia, 2021, 38, 1-10.	2.5	16
7	Suppressing DRP1-mediated mitochondrial fission and mitophagy increases mitochondrial apoptosis of hepatocellular carcinoma cells in the setting of hypoxia. Oncogenesis, 2020, 9, 67.	4.9	46
8	2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surgery and Nutrition, 2020, 9, 452-463.	1.5	267
9	Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. Journal of Hematology and Oncology, 2020, 13, 47.	17.0	84
10	Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 571-580.	10.7	373
11	Norepinephrine-stimulated HSCs secrete sFRP1 to promote HCC progression following chronic stress via augmentation of a Wnt16B/β-catenin positive feedback loop. Journal of Experimental and Clinical Cancer Research, 2020, 39, 64.	8.6	9
12	Intermittent hypoxia alleviates increased VECF and pro‑angiogenic potential in liver cancer cells. Oncology Letters, 2019, 18, 1831-1839.	1.8	26
13	Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications. Clinical and Translational Gastroenterology, 2019, 10, e00006.	2.5	36
14	A new substage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1984-1991.	2.8	7
15	A new prediction model for prognosis of patients with intermediate-stage HCC after conventional transarterial chemoembolization: an internally validated study. Journal of Cancer, 2019, 10, 6535-6542.	2.5	6
16	Angiogenesis enhanced by treatment damage to hepatocellular carcinoma through the release of <scp>GDF</scp> 15. Cancer Medicine, 2018, 7, 820-830.	2.8	27
17	The Rho GTPase Rnd1 inhibits epithelial–mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. Cell Death and Disease, 2018, 9, 486.	6.3	18
18	Prognostic Nomogram Based on Histological Characteristics of Fibrotic Tumor Stroma in Patients Who Underwent Curative Resection for Intrahepatic Cholangiocarcinoma. Oncologist, 2018, 23, 1482-1493.	3.7	26

ZHENG-GANG REN

#	Article	IF	CITATIONS
19	Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment. BMC Cancer, 2018, 18, 901.	2.6	49
20	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). Liver Cancer, 2018, 7, 235-260.	7.7	426
21	Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3β/β-catenin pathway. Oncology Reports, 2017, 37, 1725-1735.	2.6	40
22	Activated hepatic stellate cells secrete periostin to induce stem cell-like phenotype of residual hepatocellular carcinoma cells after heat treatment. Scientific Reports, 2017, 7, 2164.	3.3	33
23	Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment. Cancer Science, 2017, 108, 1778-1786.	3.9	39
24	Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells. Gene, 2017, 596, 53-88.	2.2	27
25	ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway. Journal of Experimental and Clinical Cancer Research, 2017, 36, 166.	8.6	79
26	Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. Oncotarget, 2017, 8, 13293-13303.	1.8	39
27	Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2017, 6, 387-396.	1.5	54
28	Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 442-449.	2.8	14
29	Herbal Compound <i>Songyou Yin</i> and Moderate Swimming Suppress Growth and Metastasis of Liver Cancer by Enhancing Immune Function. Integrative Cancer Therapies, 2016, 15, 368-375.	2.0	29
30	Over expression of hyaluronan promotes progression of HCC via CD44-mediated pyruvate kinase M2 nuclear translocation. American Journal of Cancer Research, 2016, 6, 509-21.	1.4	6
31	Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pairs analysis. American Journal of Cancer Research, 2016, 6, 2109-2116.	1.4	19
32	The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells. Oncotarget, 2015, 6, 40068-40080.	1.8	12
33	Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 3970.	3.3	19
34	Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling. Journal of Hematology and Oncology, 2015, 8, 23.	17.0	136
35	<i>Clostridium perfringens</i> infection after transarterial chemoembolization for large hepatocellular carcinoma. World Journal of Gastroenterology, 2015, 21, 4397.	3.3	14
36	Dynamic Expression Patterns of Differential Proteins during Early Invasion of Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e88543.	2.5	29

ZHENG-GANG REN

#	Article	IF	CITATIONS
37	Maintenance of Stemness in Oxaliplatin-Resistant Hepatocellular Carcinoma Is Associated with Increased Autocrine of IGF1. PLoS ONE, 2014, 9, e89686.	2.5	33
38	Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Primary Liver Cancer: A Meta-Analysis. PLoS ONE, 2014, 9, e96072.	2.5	101
39	Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma. BMC Cancer, 2014, 14, 849.	2.6	74
40	Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria. BMC Gastroenterology, 2014, 14, 11.	2.0	24
41	Goosecoid Promotes the Metastasis of Hepatocellular Carcinoma by Modulating the Epithelial-Mesenchymal Transition. PLoS ONE, 2014, 9, e109695.	2.5	27
42	Incomplete Radiofrequency Ablation Enhances Invasiveness and Metastasis of Residual Cancer of Hepatocellular Carcinoma Cell HCCLM3 via Activating β-Catenin Signaling. PLoS ONE, 2014, 9, e115949.	2.5	58
43	Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: A retrospective control study. World Journal of Gastroenterology, 2004, 10, 2791.	3.3	85